8-K: Centessa Pharmaceuticals Reports Positive Phase 1 Data for ORX750 and Reallocates $200 Million to Orexin Program

Centessa Pharmaceuticals announced positive interim Phase 1 data for its lead orexin agonist, ORX750, and a strategic shift to focus on its orexin program, reallocating $200 million from its discontinued SerpinPC program.

Summary

• Centessa Pharmaceuticals reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company announced positive interim data from its Phase 1 clinical study of ORX750, an orexin receptor 2 (OX2R) agonist, showing significant improvements in wakefulness in sleep-deprived healthy volunteers.
• The company has initiated a Phase 2a clinical study of ORX750 in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), with data expected in 2025.
• Centessa is advancing ORX142 in IND-enabling studies for neurological, neurodegenerative, and psychiatric disorders, with clinical data in healthy volunteers planned for 2025.
• ORX489 has been nominated as a third OX2R agonist development candidate and is entering IND-enabling studies.
• The company has strategically decided to discontinue the clinical development of SerpinPC, a move that will save approximately $200 million, which will be reallocated to the OX2R agonist program.
• Centessa reported $518.4 million in cash, cash equivalents, and short-term investments as of September 30, 2024, with a cash runway extending into mid-2027.
• Research and development expenses were $33.9 million for the third quarter of 2024, compared to $28.2 million for the same period in 2023.
• The net loss attributable to ordinary shareholders was $42.6 million for the third quarter of 2024, compared to $38.6 million for the third quarter of 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data for ORX750, a strategic reallocation of resources, and a solid cash position. The discontinuation of SerpinPC is a negative, but the overall sentiment is positive due to the focus on the promising orexin program.

Positives

• ORX750 demonstrated significant improvements in wakefulness and sleep latency in Phase 1 trials.
• ORX750 has a favorable safety and tolerability profile with no serious adverse events reported.
• The company has initiated a Phase 2a study for ORX750, which could lead to first-in-class status in NT2 and IH.
• Centessa has a strong cash position of $518.4 million, providing a runway into mid-2027.
• The strategic decision to discontinue SerpinPC and reallocate resources to the orexin program is a positive move to focus on promising assets.
• The company has a growing pipeline of OX2R agonists with potential applications in various neurological and psychiatric disorders.
• The company successfully completed a public offering, raising $242.7 million in net proceeds.

Negatives

• The company has decided to discontinue the clinical development of SerpinPC, which may be seen as a setback for that program.
• The company reported a net loss of $42.6 million for the third quarter of 2024, an increase from $38.6 million in the same period of 2023.
• Research and development expenses increased to $33.9 million for the third quarter of 2024, compared to $28.2 million for the same period in 2023.

Risks

• The success of the OX2R agonist program is dependent on the results of ongoing and future clinical trials.
• There are risks associated with the development of new drug candidates, including safety and efficacy concerns.
• The company faces competition from other pharmaceutical companies developing treatments for sleep-wake disorders.
• The company's financial performance is subject to market conditions and the success of its clinical programs.
• There are risks associated with the company's ability to obtain regulatory approvals for its drug candidates.
• The company's cash runway is dependent on its ability to manage expenses and achieve milestones.

Future Outlook

The company expects to share Phase 2a data for ORX750 in 2025 and initiate clinical development of ORX142 with data expected in 2025. The company anticipates its cash runway will extend into mid-2027.

Management Comments

• The totality of data across our OX2R agonist program continues to reinforce the strength of our discovery engine and the therapeutic potential of these assets across a broad spectrum of disorders, said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
• We aim to generate data across all three indications in 2025, which could enable ORX750 to be first-in-class in NT2 and IH, said Mario Alberto Accardi PhD, President of Centessas Orexin Program.
• Moving forward, we intend to prioritize our resources and reallocate net savings of approximately $200 million associated with the planned commercial launch of SerpinPC towards expanding our potential best-in-class OX2R agonist franchise, where we see significant opportunities to both address unmet patient needs and create shareholder value, stated John Crowley, Chief Financial Officer.

Industry Context

This announcement highlights the growing interest in orexin agonists for the treatment of sleep-wake disorders and other neurological conditions. Centessa's focus on its OX2R agonist program aligns with the industry trend of developing targeted therapies for specific patient populations. The discontinuation of the SerpinPC program reflects the competitive landscape in hemophilia B treatment and the need for companies to prioritize their resources.

Comparison to Industry Standards

• The reported MWT results for ORX750, showing a mean sleep latency of 34 minutes at the 3.5mg dose, are comparable to or better than some existing treatments for excessive daytime sleepiness.
• The company's focus on developing a once-daily oral dosing regimen for ORX750 aligns with industry trends towards patient-friendly drug delivery methods.
• The decision to discontinue SerpinPC due to the evolving treatment landscape for hemophilia B is a common practice in the pharmaceutical industry, where companies must adapt to new competitive products.
• The company's cash runway into mid-2027 is a positive sign, as many biotech companies struggle to secure long-term funding.
• Compared to companies like Jazz Pharmaceuticals, which markets Xyrem and Xywav for narcolepsy, Centessa is still in the clinical development phase, but its ORX750 data suggests a potential competitor in the future.
• The company's approach to developing multiple OX2R agonists is similar to other companies that are exploring different molecules within the same target class to address various indications.

Stakeholder Impact

• Shareholders will benefit from the company's focus on its promising orexin program and the potential for future value creation.
• Patients with narcolepsy and idiopathic hypersomnia may benefit from the development of new treatment options.
• Employees may experience changes in their roles and responsibilities due to the reallocation of resources.
• The discontinuation of the SerpinPC program may impact the stakeholders involved in that program.

Next Steps

• The company will continue the Phase 2a clinical study of ORX750 in patients with NT1, NT2, and IH.
• The company will advance ORX142 through IND-enabling studies and initiate clinical development.
• The company will enter ORX489 into IND-enabling studies.
• The company will present Phase 1 clinical data for ORX750 at a medical conference in Q2 2025.
• The company will explore strategic alternatives for SerpinPC.

Key Dates

Keywords

ORX750, Orexin Agonist, Narcolepsy, Idiopathic Hypersomnia, Sleep Disorders, Phase 2a Clinical Trial, OX2R Agonist, SerpinPC, Clinical Development, Pharmaceuticals, Biotechnology